DIAGNOSTIC TEST PANEL 522
Systemic Sclerosis/Scleroderma
Diagnostic test panel for ANA (HEp-2) and antibodies against ANA specificities (Sm, nRNP, SSA/Ro60, SSB, Scl-70, Jo-1). For suspicion of Sjögren's syndrome
SJOGREN’S SYNDROME
Indication
Suspicion of primary Sjögren’s syndrome.
Interpretation
Primary Sjögren’s syndrome is an inflammatory disease, where the symptoms are due to reduced function of salivary and lachrymal glands. The patient suffers from dry mouth, a feeling of gravel in the eyes (Keratoconjunctivitis sicca). Extraglandular symptoms occur and usually from skin, joints, muscles and thyroidea. 2.5% of the patients develop non-Hodgkin’s lymphoma. ANA is positive in about 70% of patients with Sjögren’s syndrome, usually with speckled fluorescence. In about 80% of the cases the patients have antibodies directed against Ro/SSA and about 70% have antibodies directed against La/SSB. In vasculitis in connection with Sjögren’s syndrome and systemic lupus erythematosus, anti-SSA and anti-SSB rise at the same time until some year before these manifestations emerge. Sjögren’s syndrome also occurs secondarily to other rheumatic diseases, in particular rheumatoid arthritis. In secondary Sjögren’s syndrome, SSA and SSB are positive in 10-15% of the cases.
SJOGREN’S SYNDROME/ SCLERODERMA/SYSTEMIC SCLEROSIS
Indication
Suspicion of scleroderma or systemic sclerosis. In-depth analysis is ordered when diagnosis has been established or if there is a strong suspicion of scleroderma/systemic sclerosis and when it is desired to differentiate between sub-entities. As shown in the investigation algorithm below, the analysis may be extended with determination of antibodies against PM-Scl (p100), Th/To, RNA polymerase, and Fibrillarin (see these analyses in the Individual tests list and packet 527).
Clinical background
A disease with an unclear etiology, which affects many organ systems, mainly the skin and the blood vessels but the lungs and the gastrointestinal tract may also be affected. Kidney, heart and muscle symptoms are less common. The most common clinical characteristics are dermatofibrosis of varying intensity and extent and circulation disorders in fingers and toes (Raynaud’s phenomenon). The disease is usually divided into different forms, such as:
- Limited form (usually in the face and distally toward the elbow and knee) fits in with CREST syndrome.
- Diffuse forms of skin symptoms, proximally to the elbow and on the body.
- Overlap syndrome.
Tests included in panel
Need pricing information?
How to order
This test panel is available worldwide for hospitals, clinics, and physicians.
-
Print and complete the request form
Download the request form. Clearly state the name and phone number of the referring hospital, clinic, or physician. -
Prepare your samples
Serum: At least 0.5 mL serum (plain serum tubes without additives).
-
Send samples and request form
Within Sweden
Samples can be sent at room temperature to:
Envelopes and smaller boxes:
Wieslab AB, Box 50117, 20211 Malmö, Sweden
Larger boxes and frozen samples:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
International
Samples can be sent at room temperature to:
Wieslab AB, Lundavägen 151, 21224 Malmö, Sweden
Last updated: 2025-08-18
